Clinical implications of low-to-intermediate trials for primary prevention of atherosclerotic CVD and risk stratification with N-terminal pro-B-type natriuretic peptide in the Rotterdam Study
8 April 2017 (08:30 - 12:30)
Organised by:
Abstract
About the speaker
Rotterdam (Netherlands (The))
15 More presentations in this session
Access the full session
The Event
EuroPrevent 2017
8 April 2017
08:30 CET
